Loading
Life sciences · Journal article
Frontiers in Pharmacology · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Introduction Metabolic reprogramming and immune evasion are tightly linked in gastric cancer (GC), yet metabolic signatures are rarely leveraged to guide treatment decisions or herbal small molecule drug discovery. Methods We profiled glycolysis, lipid, and tyrosine metabolism pathways across the TCGA-STAD and GSE62254 cohorts, identified prognostic metabolic subtypes, and distilled these findings into a three-gene risk signature ( VCAN, NOS1, LCT ). The signature was validated in the external GSE62254 cohort and assessed for associations with immune cell infiltration patterns, tumor mutational burden, microsatellite instability status, and tumor immune dysfunction and exclusion (TIDE) scores. Rather than following the conventional compound-to-target screening paradigm, we reversed the pipeline: starting from the signature genes, we queried PubChem for herbal bioactive small molecules targeting the three signature proteins ( VCAN, NOS1, and LCT ) and evaluated candidates through molecular docking, 100-ns molecular dynamics simulations, and comprehensive ADMET profiling. The anti-GC activity of the leading candidate was further examined in AGS and HGC27 cells. Results Three prognostic metabolic subtypes with distinct survival outcomes and immune microenvironment compositions were identified. The model robustly stratified patients into high- and low-risk groups and showed significant correlations with immune cell infiltration patterns, tumor mutational burden, microsatellite instability status, and TIDE scores. Notopterol (a furanocoumarin) and amentoflavone (a biflavonoid) emerged as the most promising hits. Notopterol, in particular, exhibited favorable drug-like properties and potent anti-GC activity: it suppressed the proliferation and migration of AGS and HGC27 cells in a concentration-dependent manner. Discussion These findings establish a metabolism-driven prognostic framework and nominate notopterol as a lead herbal-derived small molecule for further development in gastric cancer therapy; its correlations with immunotherapy-related features indicate potential utility for immunotherapy patient selection.